This phase III trial is comparing immunotherapy (with nivolumab and ipilimumab) with the 'extreme study regimen' as a first line treatment for patients with a squamous cell carcinoma of the head and neck that has come back or has spread to other parts of the body.
This trial is treating patients with Squamous Cell Cancer of the Head and Neck (including the oral cavity, oropharynx, hypopharynx or larynx).
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment, but your cancer has come back.
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination With Ipilimumab Versus Extreme Study Regimen (Cetuximab + Cisplatin/Carboplatin + Fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Bristol-Myers Squibb (BMS)
The main purpose of this study is to compare nivolumab and ipilimumab with the Extreme study regimen as first line treatment in patients with recurrent or metastatic squamous cell of the head and neck cancer
Not Recruiting Hospitals Read More